What does DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ do?

DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ is a specialist medical practice in Brussel. Private Limited, started on 9 December 2021.

What is the address of DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ?

The registered office of DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ is located at Jan Sobieskilaan 4, 1020 Brussel.

Is DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ still active?

Yes. According to the CBE (19 September 2026) DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ is active, legal situation “Normale toestand”, started on 9 December 2021.

Is DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ registered on Peppol?

Yes, DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ is registered on the Peppol network with ID 0208:0778461424.

What is the enterprise number of DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ?

The enterprise number of DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ is BE0778461424.

When was DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ founded?

DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ was founded on 9 December 2021.

Who are the directors of DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ?

According to the 2025 annual accounts, the directors of DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ are: SABINE MARICHAL.

Is DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 9 December 2021; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ make in 2025?

DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ posted a profit after taxes of € 138,700 in financial year 2025.

What is the revenue of DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ?

As a small company, DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 172,410.

DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ (Private Limited)

Dossier DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ, printed on 19 September 2026 from databakkes.be/en/0778461424/dr-marichal-onco-hematologie-et-sante. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ from Brussel, company number BE0778461424, closed financial year 2025 with a result of € 138,700 after tax. For that financial year DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ recorded a gross margin of € 172,410 and equity of € 314,505. Compared with financial year 2024, the result moved from € 120,016 to € 138,700. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.

What it is worth Growing

€ 314,505

▲ 23% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 138,700

▲ 16% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 201,174

▲ 199% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 80,000 paid out

58 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 742

▼ 50% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 1,413

▲ 58% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 29,664

▲ 94% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 184,139 Gross margin 2022: € 184,139 First fiscal year in the series	€ 134,843 Gross margin 2023: € 134,843 ▼ 27% vs 2022 (€ 184,139) Unfavourable step	€ 151,914 Gross margin 2024: € 151,914 ▲ 13% vs 2023 (€ 134,843) Favourable step	€ 172,410 Gross margin 2025: € 172,410 ▲ 13% vs 2024 (€ 151,914) Favourable step	▲ 13%
Profit after taxes	€ 130,662 Profit after taxes 2022: € 130,662 First fiscal year in the series	€ 105,127 Profit after taxes 2023: € 105,127 ▼ 20% vs 2022 (€ 130,662) Unfavourable step	€ 120,016 Profit after taxes 2024: € 120,016 ▲ 14% vs 2023 (€ 105,127) Favourable step	€ 138,700 Profit after taxes 2025: € 138,700 ▲ 16% vs 2024 (€ 120,016) Favourable step	▲ 16%
Equity	€ 100,662 Equity 2022: € 100,662 First fiscal year in the series	€ 170,789 Equity 2023: € 170,789 ▲ 70% vs 2022 (€ 100,662) Favourable step	€ 255,806 Equity 2024: € 255,806 ▲ 50% vs 2023 (€ 170,789) Favourable step	€ 314,505 Equity 2025: € 314,505 ▲ 23% vs 2024 (€ 255,806) Favourable step	▲ 23%
Total debts	€ 5,207 Total debts 2022: € 5,207 First fiscal year in the series	€ 4,418 Total debts 2023: € 4,418 ▼ 15% vs 2022 (€ 5,207) Favourable step	€ 16,147 Total debts 2024: € 16,147 ▲ 265% vs 2023 (€ 4,418) Unfavourable step	€ 70,062 Total debts 2025: € 70,062 ▲ € 53,915 vs 2024 (€ 16,147) Unfavourable step	▲ € 53,915
Cash	€ 74,993 Cash 2022: € 74,993 First fiscal year in the series	€ 43,663 Cash 2023: € 43,663 ▼ 42% vs 2022 (€ 74,993) Unfavourable step	€ 67,386 Cash 2024: € 67,386 ▲ 54% vs 2023 (€ 43,663) Favourable step	€ 201,174 Cash 2025: € 201,174 ▲ 199% vs 2024 (€ 67,386) Favourable step	▲ 199%
Retained profit	€ 95,662 Retained profit 2022: € 95,662 First fiscal year in the series	€ 165,789 Retained profit 2023: € 165,789 ▲ 73% vs 2022 (€ 95,662) Favourable step	€ 250,806 Retained profit 2024: € 250,806 ▲ 51% vs 2023 (€ 165,789) Favourable step	€ 309,505 Retained profit 2025: € 309,505 ▲ 23% vs 2024 (€ 250,806) Favourable step	▲ 23%
Dividend	€ 35,000 Dividend 2022: € 35,000 First fiscal year in the series	€ 35,000 Dividend 2023: € 35,000 Unchanged (€ 35,000) Unchanged	€ 35,000 Dividend 2024: € 35,000 Unchanged (€ 35,000) Unchanged	€ 80,000 Dividend 2025: € 80,000 ▲ 129% vs 2024 (€ 35,000) Unchanged	▲ 129%
Balance sheet total	€ 105,869 Balance sheet total 2022: € 105,869 First fiscal year in the series	€ 175,207 Balance sheet total 2023: € 175,207 ▲ 65% vs 2022 (€ 105,869) Unchanged	€ 271,953 Balance sheet total 2024: € 271,953 ▲ 55% vs 2023 (€ 175,207) Unchanged	€ 384,567 Balance sheet total 2025: € 384,567 ▲ 41% vs 2024 (€ 271,953) Unchanged	▲ 41%

Key figures of DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ?

What happened at DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 22, 2026 New annual accounts for financial year 2025: profit of € 138,700 (▲ 16% vs 2024). Source: NBB ↗
Dec 9, 2021 Start of the company according to the CBE. KBO

In short

From € 130,662 profit in 2022 to € 138,700 profit in 2025.

Paid € 164,795 in corporate taxes since 2022.

Best year ever: 2025, with € 138,700 profit.

Paid out € 185,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ? We notify you, reason included.

Follow DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

SABINE MARICHAL

DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ

Groupement Radiothérapie Hématologie Oncologie

Behind DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ is SABINE MARICHAL. SABINE MARICHAL is also behind Groupement Radiothérapie Hématologie Oncologie.

See the full network in the app

Directors

According to the 2025 annual accounts

SABINE MARICHAL

Director

Also active at: Groupement Radiothérapie Hématologie Oncologie

Establishments

Establishment units

Physical locations of this company

Registered office

Jan Sobieskilaan 4

1020 Brussel

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.

All companies at this address →

Cardiologie Peter Goethals

€ 178,794 gross margin · 2025

"Association des copropriétaires de l'avenue Jean Sobieski, 4" à Bruxelles, avenue Jean Sobieski, 4

CARDIO DONANO

€ 53,974 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0778.461.424

VAT number

BE 0778.461.424

Registered office

Jan Sobieskilaan 4, 1020 Brussel

Names & denominations

DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ · O.H.S.

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

9 December 2021

Peppol

Active · Active since 31 Mar 2026

Activities · NACE

Activiteiten van medisch specialisten

Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg

Overige gespecialiseerde wetenschappelijke en technische activiteiten

View on CBE Public ↗ Annual accounts (NBB) ↗